Table 5.
Comparison of T2-high and T2-low patients*
| T2-low (n=210) | T2-high (n=992) | P value | |
| Age at first assessment | 48.1 (15.1) | 48.8 (14.3) | 0.522 |
| 18–34 | 47 (22.4%) | 173 (17.5%) | |
| 35–54 | 84 (40.0%) | 456 (46.1%) | |
| 55–79 | 78 (37.1%) | 360 (36.4%) | |
| 80+ | 1 (0.5%) | 1 (0.1%) | |
| Age at onset of symptoms | 17.1 (16.6) | 25.9 (19.1) | <0.001 |
| <12 | 96 (53.6%) | 282 (31.0%) | |
| 12–18 | 18 (10.1%) | 88 (9.7%) | |
| >18 | 65 (36.3%) | 540 (59.3%) | |
| Gender | 0.076 | ||
| Female | 141 (67.1%) | 601 (60.6%) | |
| Male | 69 (32.9%) | 391 (39.4%) | |
| Ethnicity | 0.012 | ||
| Caucasian | 178 (85.2%) | 748 (76.4%) | |
| Non-Caucasian | 31 (14.8%) | 231 (23.6%) | |
| BMI (kg/m2) | 32.1 (7.8) | 30.2 (6.7) | <0.001 |
| Smoking status | <0.001 | ||
| Never smoked | 123 (59.1%) | 688 (69.7%) | |
| Ex-smoker | 68 (32.7%) | 277 (28.1%) | |
| Current smoker | 17 (8.2%) | 22 (2.2%) | |
| Atopic disease | 148 (71.5%) | 607 (61.8%) | 0.028 |
| Spinal bone density (T-Score) | −1.0 (1.4) | −0.7 (1.4) | 0.010 |
| Femoral neck bone density (T-Score) | −0.5 (1.1) | −0.4 (1.1) | 0.314 |
| FEV1 (% predicted) | 66.2 (22.6) | 66.5 (20.6) | 0.858 |
| FVC (% predicted) | 80.6 (19.8) | 84.4 (18.7) | 0.020 |
| FEV1/FVC | 66.7 (14.8) | 63.6 (13.7) | 0.007 |
| Residual volume (% predicted) | 122.8 (44.1) | 128.1 (44.7) | 0.450 |
| Total lung capacity (% predicted) | 96.2 (22.8) | 103.3 (17.7) | 0.016 |
| ACQ6 Score | 3.1 (1.3) | 2.9 (1.4) | 0.161 |
| Rescue steroids in last year | 4 (1, 7) | 4 (2, 8) | 0.014 |
| Hospital admissions for asthma in last year | 0 (0, 2) | 0 (0, 1) | 0.005 |
| Invasive ventilations (ever) | 26 (15.5%) | 73 (8.4%) | <0.001 |
| Eczema | 8 (3.9%) | 29 (3.0%) | 0.341 |
| Nasal polyps | 22 (10.8%) | 190 (19.5%) | 0.006 |
| Gastro-oesophageal reflux | 41 (20.2%) | 173 (17.8%) | 0.317 |
| Depression or anxiety | 25 (12.3%) | 74 (7.6%) | 0.040 |
| Blood eosinophil count (N/109 L) | 0.07 (0.01, 0.10) | 0.50 (0.30, 0.70) | <0.001 |
| Highest blood eosinophil count (N/109 L)ϯ | 0.35 (0.13, 0.60) | 0.76 (0.50, 1.15) | <0.001 |
| FeNO (ppb) | 14.0 (9.0, 18.0) | 60.0 (39.0, 94.0) | <0.001 |
| IgE (IU/mL) | 155 (34, 437) | 189 (67, 509) | 0.007 |
| Maintenance oral steroids | 121 (57.9%) | 415 (42.1%) | <0.001 |
| Maintenance oral steroid dose (mg) | 10 (5, 20) | 10 (5, 15) | 0.013 |
| Inhaled steroid dose (mcg, BDP equivalent) | 2000 (1600, 2000) | 2000 (1600, 2000) | 0.733 |
| LAMA | 116 (56.0%) | 527 (54.2%) | 0.790 |
| Theophylline | 73 (35.1%) | 228 (23.4%) | 0.001 |
| SABA | 196 (94.2%) | 937 (95.3%) | 0.801 |
| Leukotriene receptor antagonist | 107 (53.0%) | 488 (50.8%) | 0.784 |
| Maintenance macrolide | 23 (11.4%) | 76 (7.9%) | 0.248 |
| Nebuliser | 73 (35.1%) | 189 (19.6%) | <0.001 |
| Prior anti-IgE therapy | 36 (17.3%) | 99 (10.2%) | 0.008 |
*Mean (SD), median (IQR) or count (%) as appropriate.
†Highest blood count is the highest recorded in available prior medical records.
ACQ, Asthma Control Questionnaire; BMI, body mass index; FeNO, fractional exhaled nitric oxide; LAMA, long-acting antimuscarinic antagonist; SABA, short acting β2-agonist.